HC Wainwright Predicts Higher Earnings for COMPASS Pathways

COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - Stock analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for COMPASS Pathways in a research note issued to investors on Thursday, February 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.34) per share for the quarter, up from their previous forecast of ($0.51). HC Wainwright currently has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways' Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.38) EPS and FY2027 earnings at ($0.92) EPS.

CMPS has been the topic of several other reports. Maxim Group lowered their target price on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reaffirmed an "outperform" rating and set a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $30.60.

COMPASS Pathways Stock Up 0.9 %

Shares of COMPASS Pathways stock traded up $0.04 on Monday, reaching $4.54. The company's stock had a trading volume of 802,254 shares, compared to its average volume of 1,290,977. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.75. The firm's fifty day simple moving average is $4.09 and its two-hundred day simple moving average is $5.39. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $310.63 million, a price-to-earnings ratio of -2.06 and a beta of 2.28.

Institutional Trading of COMPASS Pathways

A number of large investors have recently modified their holdings of CMPS. RTW Investments LP bought a new position in COMPASS Pathways in the fourth quarter worth approximately $11,714,000. Altium Capital Management LLC bought a new stake in shares of COMPASS Pathways in the 4th quarter valued at about $5,384,000. Nantahala Capital Management LLC grew its position in shares of COMPASS Pathways by 400.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company's stock worth $3,780,000 after buying an additional 800,000 shares during the last quarter. Tang Capital Management LLC purchased a new position in shares of COMPASS Pathways in the 4th quarter worth approximately $3,780,000. Finally, Sio Capital Management LLC boosted its stake in COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock valued at $5,762,000 after acquiring an additional 621,222 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.